Skip Navigation



Glycobiology Advance Access published online on October 30, 2002
Glycobiology, doi:10.1093/glycob/cwg005
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
13/2/129    most recent
cwg005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wuhrer, M.
Right arrow Articles by Geyer, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wuhrer, M.
Right arrow Articles by Geyer, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Submitted on July 2, 2002
Revised on August 29, 2002
Accepted on August 30, 2002

© 2002 Oxford University Press

ORIGINAL ARTICLES

A novel GlcNAc{alpha}1-HPO3-6Gal(1-1)ceramide antigen and alkylated inositol-phosphoglycerolipids expressed by the liver-fluke Fasciola hepatica

Manfred Wuhrer 1, Christiane Grimm 1, Ulrich Zähringer 2, Roger D. Dennis 1, Clemens M. Berkefeld 1, Mohamed A. Idris 3, Rudolf Geyer 4*

1 Institute of Biochemistry, Medical Faculty, University of Giessen, D-35392 Giessen, Germany
2 Division of Immunochemistry, Research Center Borstel, Center for Medicine and Biosciences, D-23845 Borstel, Germany
3 Department of Microbiology and Immunology, College of Medicine, Sultan Qaboos University, Muscat, Sultanate of Oman
4 Biochemisches Institut, Universität Giessen, Friedrichstrasse 24, D-35392 Giessen, German; Institute of Biochemistry, Medical Faculty, University of Giessen, D-35392 Giessen, Germany

* To whom correspondence should be addressed. E-mail: rudolf.geyer{at}biochemie.med.uni-giessen.de.

Abstract

The acidic (glyco)lipids of the parasitic liver-fluke Fasciola hepatica exhibited two different, phosphate-containing species designated AL-I and AL-II, which were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, electrospray ionization-ion trap-mass spectrometry, nuclear magnetic resonance, methylation analysis and combined gas chromatography-mass spectrometry in conjunction with HF-treatment. AL-I was structurally determined as 1-O-hexadecyl-sn-glycerol-3-phosphoinositol, an ether-bond variant of lysophosphatidylinositol. The structure of AL-II was shown to be GlcNAc{alpha}1-HPO3-6Gal(1-1)ceramide. Ceramide analysis revealed as major components 2-hydroxyoctadecanoic acid [18:0(2-OH)] together with C18- and C20-phytosphingosines. AL-II was apparently highly antigenic and strongly recognized by both animal- and human-F. hepatica infection sera. Furthermore, inhibition-enzyme-linked immunosorbent assays revealed that the unusual antigenic determinant GlcNAc-phosphate might have a potential in the serodiagnosis of F. hepatica infections.


Keywords: electrospray mass spectrometry, liver-fluke glycolipids, oligosaccharide structural analysis, parasitic trematode
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GlycobiologyHome page
M. Wuhrer, C. Grimm, R. D. Dennis, M. A. Idris, and R. Geyer
The parasitic trematode Fasciola hepatica exhibits mammalian-type glycolipids as well as Gal({beta}1-6)Gal-terminating glycolipids that account for cestode serological cross-reactivity
Glycobiology, February 1, 2004; 14(2): 115 - 126.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.